95% of these Bio Techs are the same, they announce 1st, 2nd and 3rd results only to find that
the cure affects something else and the FDA shoots it down...look at what just happened to CLSN..all the longs thought they were going to get rich and they bet the farm..well they lost the farm. These longs were not idiots, they did the DD but that was not enough because everything you read is second hand information..truth is you do not know until you know and you do not know until the bank tells you that the check cleared and the money is ready to spend.
Celsion (NASDAQ: CLSN ) has finally released data for its closely watched phase
3 HEAT trial after starving investors for the entire month of January. The
results? The study evaluating ThermoDox and radiofrequency ablation (RFA) failed
to meet its primary endpoint of improving progression-free survival (PFS) by at
least 33% over the placebo in patients with hepatocellular carcinoma, or HCC.
Secondary endpoints didn't fare much better."
"One major red flag in the ability to prove statistical significance was the
fact that the trial progressed to phase 3 after evaluating data in just nine HCC
patients in phase 1/2. Going from nine data points to 380 is quite a leap.
Another red flag was the large improvement (33%) over placebo needed to meet the
primary endpoint. Previous large-scale trials have demonstrated the power of RFA
in treating HCC patients without the aid of a chemotherapy drug, which might
suggest that adding a drug would not result in a statistically significant
improvement. In hindsight, this could have been a major reason to remain
cautious about the chances of success of the HEAT trial."
- "justpumpmeup" wrote:
CLSN went straight from phase 1 to phase 3. Quite unlike of case here, when I
did my DD on CLSN, I found very little data from early trials to support a case
for success. Reolysin by comparison has results from numerous trials that,
although not randomized, do consistently indicate benefit to the patient.
The patients in the control arm of the CSLN/ThermoDox trial performed about
20 percent better than expected, whereas those on the drug ThermoDox performed
worse than anticipated, according to Roth Capital Partners analyst Joseph
The results of ThermoDox trial have suggested that patients who received
CSLN's Theromodox were actually worse-off than those who just received the
Conversely, the early analysis (December 13, 2013) of the ONCY Phase III
clinical trial has shown that the Reolysin/carbo/tax arm of the double blind
trial is performing significantly better than the control of carbo/tax alone.
There have been a lot of trials with Reolysin. The human race has lived with this virus for probably millions of years. Our bodies seem to have built a pretty good immune response to it. In all trials so far the main side affect has been mild flu like symptoms AFAIK.
Unless something radical an unexpected happens I don't see side affects derailing Reolysin.
That is the "cure", like your use of that word, causes mild flu like symptoms. I can live with that.